Clinical Trial Update: Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating docetaxel alone or with enzalutamide for metastatic castration-resistant prostate cancer previously treated with abiraterone, spanni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Zhongnan Hospital | Conditions: Prostate Cancer, Castrate Resistant Prostate Cancer | Phase 2, Phase 3 | Status: UNKNOWN